谢 婷,杨青岩

2型糖尿病是一种影响全世界人民身心健康的代谢性疾病，且其近年发病率在我国及世界均逐年上升。2型糖尿病的并发症是影响2型糖尿病患者生活质量及死亡的主要原因，其中动脉粥样硬化性心血管疾病是2型糖尿病的主要并发症之一，也是2型糖尿病患者致残、致死的主要原因。现本文就2型糖尿病并发动脉粥样硬化性心血管疾病的流行病学特征、发病机制、防治措施进行综述，为临床诊治提供参考。

2型糖尿病；动脉粥样硬化性心血管疾病；心血管疾病

[1] AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE C. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024 [J]. Diabetes care, 2024, 47(Suppl 1): S179-S218. [2] PAN X R, YANG W Y, LI G W, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group [J]. Diabetes care, 1997, 20(11): 1664-9. [3] WANG L, PENG W, ZHAO Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018 [J]. Jama, 2021, 326(24): 2498-506. [4] WHITING D R, GUARIGUATA L, WEIL C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 [J]. Diabetes research and clinical practice, 2011, 94(3): 311-21. [5] MAGLIANO D J, BOYKO E J, COMMITTEE I D F D A T E S. IDF Diabetes Atlas [M]. Idf diabetes atlas. Brussels; International Diabetes Federation© International Diabetes Federation, 2021. 2021. [6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志,2021,13(4):315-409. [7] EINARSON T R, ACS A, LUDWIG C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017 [J]. Cardiovascular diabetology, 2018, 17(1): 83. [8] MOSENZON O, ALGUWAIHES A, LEON J L A, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries [J]. Cardiovascular diabetology, 2021, 20(1): 154. [9] JIA G, BAI H, MATHER B, et al. Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights [J]. International journal of molecular sciences, 2024, 25(2). [10] BANSAL S, BURMAN A, TRIPATHI A K. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes [J]. World journal of diabetes, 2023, 14(8): 1146-62. [11] LUO S, AU YEUNG S L, SCHOOLING C M. Assessing the linear and non-linear association of HbA(1c) with cardiovascular disease: a Mendelian randomisation study [J]. Diabetologia, 2021, 64(11): 2502-10. [12] LOW WANG C C, HESS C N, HIATT W R, et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations [J]. Circulation, 2016, 133(24): 2459-502. [13] FARHAN S, REDFORS B, MAEHARA A, et al. Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study [J]. Cardiovascular diabetology, 2021, 20(1): 10. [14] S C T, LAI L C. Diabetic dyslipidaemia [J]. Practical laboratory medicine, 2021, 26: e00248. [15] MELNIKOV I, KOZLOV S, SABUROVA O, et al. Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives [J]. International journal of molecular sciences, 2023, 24(3). [16] TSIOUFIS P, THEOFILIS P, TSIOUFIS K, et al. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches [J]. International journal of molecular sciences, 2022, 23(24). [17] DHANANJAYAN R, KOUNDINYA K S, MALATI T, et al. Endothelial Dysfunction in Type 2 Diabetes Mellitus [J]. Indian journal of clinical biochemistry : IJCB, 2016, 31(4): 372-9. [18] KULOVIC-SISSAWO A, TOCANTINS C, DINIZ M S, et al. Mitochondrial Dysfunction in Endothelial Progenitor Cells: Unraveling Insights from Vascular Endothelial Cells [J]. Biology, 2024, 13(2). [19] ALTALHI R, PECHLIVANI N, AJJAN R A. PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target [J]. International journal of molecular sciences, 2021, 22(6). [20] SAFDAR N Z, KIETSIRIROJE N, AJJAN R A. The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk [J]. International journal of molecular sciences, 2023, 24(20). [21] MARX N, FEDERICI M, SCHüTT K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes [J]. European heart journal, 2023, 44(39): 4043-140. [22] COMMITTEE A D A P P. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024 [J]. Diabetes care, 2024, 47(Suppl 1): S158-s78. [23] SATTAR N, LEE M M Y, KRISTENSEN S L, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials [J]. The lancet Diabetes & endocrinology, 2021, 9(10): 653-62. [24] MARFELLA R, PRATTICHIZZO F, SARDU C, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes [J]. Cardiovascular diabetology, 2024, 23(1): 10. [25] MIHAYLOVA B, EMBERSON J, BLACKWELL L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials [J]. Lancet (London, England), 2012, 380(9841): 581-90. [26] O'DONOGHUE M L, GIUGLIANO R P, WIVIOTT S D, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease [J]. Circulation, 2022, 146(15): 1109-19. [27] 崔孔勇,尹栋,丰雷,等.稳定性冠心病合并糖尿病患者药物洗脱支架置入术后延长双联抗血小板治疗的获益与风险[J].中华心血管病杂志,2022,50(5):458-65. [28] STEG P G, BHATT D L, SIMON T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes [J]. The New England journal of medicine, 2019, 381(14): 1309-20. [29] LV X, ZHANG Y, NIU Y, et al. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis [J]. Medicine, 2018, 97(15): e0256. [30] NAZARZADEH M, BIDEL Z, CANOY D, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis [J]. The lancet Diabetes & endocrinology, 2022, 10(9): 645-54.

点击下载PDF